RobGenes
All newsletters

RobGenes · The Health & Genetics Letter

Metabolic health

How can you protect muscle on a weight-loss injection?

When you fill up halfway through lunch, what stays on the plate matters. Keeping your strength deserves a place in the conversation about weight loss.

5 min read
An injection pen beside exercise gear
Editorial illustration · An injection pen beside exercise gear

Read the scale alongside your strength

Medicines such as semaglutide can reduce appetite. As weight comes down, some lean tissue may be lost alongside fat. But lean tissue is not another name for muscle: it also includes water. A body scan therefore cannot tell you exactly how much muscle you have lost. The number on the scale is useful, but it does not describe the whole change. Genetics adds context, not a replacement for this everyday picture. Your genotype is your genetic makeup; your phenotype is an observable characteristic, such as strength or body composition. When reviewing weight loss, consider what you can do as well as what you weigh. Getting up from a chair, climbing stairs and carrying groceries offer practical details to discuss.

What a muscle gene can—and cannot—tell you

A gene is a stretch of DNA containing instructions for a functional product, often a protein. A variant is a difference in the DNA sequence. ACTN3 provides instructions for alpha-actinin-3, a protein found in fast-twitch muscle fibers. This gives the gene a clear connection to muscle biology, but not a complete account of anyone’s strength. The ACTN3 variant R577X can lead to absence of this protein in people with two copies. That is compatible with healthy life. It does not mean that muscles cannot work, nor does it predict muscle loss during GLP-1 treatment. This distinction matters: a biological mechanism can be interesting without being an individual forecast. An ACTN3 result is not an exercise prescription or a reason to assume that weakness is inevitable.

Appetite has genetic biology, too

POMC connects genetics to another part of the story: energy balance. It produces a precursor from which signaling peptides are generated. Those peptides help regulate energy balance through signaling involving MC4R. This illustrates how genetic instructions contribute to biological communication, rather than simply assigning someone a fixed body weight or appetite. Rare pathogenic POMC variants can cause severe obesity beginning early in life. That specific situation is distinct from routine adult weight change and should not be inferred from feeling hungry, becoming full sooner or taking a weight-loss medicine. For this newsletter’s everyday question, the useful connection is that appetite and muscle have biological foundations. POMC and ACTN3 explain different pieces of that biology; neither provides a stand-alone plan for protecting muscle during treatment.

Make smaller meals count

When lunch suddenly feels too large, what remains on the plate becomes worth noticing. The practical question is not whether your genes demand a particular menu. It is whether smaller portions still leave room for protein foods you enjoy, such as eggs, yogurt, lentils or fish. Bring the reality of your meals into the conversation, rather than describing only the diet you intended to follow. Protein needs vary, especially when kidney disease is present, so an individual discussion is more useful than a universal target. Neither ACTN3 nor POMC, on the evidence supplied here, determines your personal protein requirement. Genetics belongs alongside nutrition and treatment context. A typical day’s eating can help your clinician understand what reduced appetite means for you in practice.

Give muscle a reason to work

Muscles respond to being used against resistance. Making room for that work is a practical companion to making room for protein. A clinician or physiotherapist can help choose exercises that fit your current strength, mobility and any joint pain. The starting point is what you can do and what needs adapting, not a genetic label that supposedly identifies your ideal workout. This is where phenotype becomes especially useful. Tell your care team whether standing from a chair, taking stairs or carrying shopping feels different. These observations do not measure muscle tissue precisely, but they add information that weight alone misses. Even an interesting ACTN3 finding cannot replace that conversation. Its role in fast-twitch fibers does not establish which exercise program you should follow during GLP-1 treatment.

Separate a genetic connection from a prediction

An association means that a genetic difference and a trait occur together in research; it does not, by itself, prove that the difference causes the trait. Causation is a stronger claim. Knowing a gene’s biological role also does not automatically show how a particular person will respond to treatment. These distinctions keep an engaging genetics story from becoming an unsupported promise. The cited research does not establish a validated single-nucleotide polymorphism, or SNP, that determines GLP-1 response. Nor does R577X predict treatment-related muscle loss. Read genetic information alongside nutrition, strength and the treatment context, rather than above them. A useful review can acknowledge what remains uncertain while still addressing concrete concerns: smaller meals, changes in everyday abilities and whether the current support fits your needs.

Sources & further reading

Educational reading to enrich your conversation with a healthcare professional, interpreted in the context of your own health and needs.